These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 2928805

  • 1. Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
    Petti MC, Mandelli F.
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):10-5. PubMed ID: 2928805
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
    Vogler WR, Velez-Garcia E, Omura G, Raney M.
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
    Candoni A, Simeone E, Tiribelli M, Malagola M, Russo D, Fanin R.
    Am J Hematol; 2009 Oct; 84(10):690-2. PubMed ID: 19731308
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
    Lambertenghi-Deliliers G, Annaloro C, Cortelezzi A, Cortellaro M, Della Volpe A, Maiolo AT, Mozzana R, Pogliani E, Pozzoli E, Polli EE.
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):16-20. PubMed ID: 2928806
    [No Abstract] [Full Text] [Related]

  • 10. Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies.
    Carella AM, Berman E, Maraone MP, Ganzina F.
    Haematologica; 1990 Feb; 75(2):159-69. PubMed ID: 2192943
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N, Sarper N, Devecioğlu O, Anak S, Eryilmaz E, Can M, Yenilmez H, Ağaoğlu L, Gedikoğlu G.
    Turk J Pediatr; 2000 Feb; 42(3):198-204. PubMed ID: 11105617
    [Abstract] [Full Text] [Related]

  • 17. [Acute myeloid leukemia trials by Japan Adult Leukemia Study Group (JALSG)].
    Miyazaki Y.
    Rinsho Ketsueki; 2009 Aug; 50(8):611-6. PubMed ID: 19915375
    [No Abstract] [Full Text] [Related]

  • 18. Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
    Shi P, Zha J, Guo X, Chen F, Fan Z, Huang F, Meng F, Liu X, Feng R, Xu B.
    Pharmacogenomics; 2013 Jan; 14(1):17-23. PubMed ID: 23252945
    [Abstract] [Full Text] [Related]

  • 19. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
    Feig SA, Ames MM, Sather HN, Steinherz L, Reid JM, Trigg M, Pendergrass TW, Warkentin P, Gerber M, Leonard M, Bleyer WA, Harris RE.
    Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.